{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:09:26Z","timestamp":1791220166133,"version":"4.1.0"},"reference-count":122,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T00:00:00Z","timestamp":1301961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The sympathetic nervous system plays a central role in the pathophysiology not only of hypertension and other cardiovascular diseases but also metabolic disorders including disturbances of glucose and lipid homeostasis. A centrally acting sympathetic agent is therefore attractive not only for lowering blood pressure, but also intervening with multiple disease processes. Older agents such as clonidine and guanabenz have numerous side effects, including sedation and dry mouth that limit their acceptability to patients. Moxonidine and the related agent rilmenidine have greatly reduced side effects, because they have reduced activity at the \u03b1<jats:sub>2<\/jats:sub>\u2010adrenergic receptors that mediate these undesirable actions. Instead, moxonidine and rilmenidine act primarily through a novel cellular site, termed the I<jats:sub>1<\/jats:sub>\u2010imidazoline receptor. The molecular biology of the I<jats:sub>1<\/jats:sub>\u2010imidazoline receptor protein has recently been described, and the cell signaling pathways linked to this protein have been characterized. Moxonidine has unique effects on a number of cell types through this unusual cellular site of action. There are multiple therapeutic implications of these cellular actions, especially for metabolic syndrome and its associated derangements in glucose and lipid metabolism. Finally, the clinical trials that seemed to identify an unfavorable outcome in severe heart failure are dissected and critiqued. We conclude that moxonidine and future successors to this agent could be of great value in treating multiple chronic diseases.<\/jats:p>","DOI":"10.1111\/j.1755-5922.2011.00268.x","type":"journal-article","created":{"date-parts":[[2011,4,7]],"date-time":"2011-04-07T01:22:17Z","timestamp":1302139337000},"page":"199-208","source":"Crossref","is-referenced-by-count":43,"title":["Pharmacological Properties of the Central Antihypertensive Agent, Moxonidine"],"prefix":"10.1111","volume":"30","author":[{"given":"Lincoln P.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Brown\u2010Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lancelot","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ernsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,5]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.69.12.985"},{"key":"e_1_2_10_3_2","first-page":"32","article-title":"Anti\u2010hyperglycemic activity of moxonidine: Metabolic and molecular effects in obese spontaneously hypertensive rats","volume":"3","author":"Friedman JE","year":"1998","journal-title":"Blood Press"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200018100-00021"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/080370598438438"},{"key":"e_1_2_10_6_2","first-page":"111","article-title":"A Vasoactive Hormone","volume":"22","author":"Srivastava BK","year":"2002","journal-title":"Int J Diab Dev Ctries"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-003-0028-7"},{"issue":"6","key":"e_1_2_10_8_2","first-page":"S50","article-title":"Insulin resistance in dilated cardiomyopathy","volume":"4","author":"Shah A","year":"2003","journal-title":"Rev Cardiovasc Med"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.29.3.700"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10762"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.11.4104"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003303421301"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000231552.10054.aa"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6681.1152"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90122-8"},{"key":"e_1_2_10_16_2","first-page":"219","article-title":"Effects of selective alfa 1 and beta 1\u2010adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity","volume":"8","author":"Andersson PE","year":"1994","journal-title":"J Hum Hypertens"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602083340607"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000028979.98877.0C"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568016052773342"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197619111"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977215593"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561067"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816040-00012"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1987.tb11220.x"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199206000-00013"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(92)90400-A"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cne.903280409"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(96)10022-5"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00095-3"},{"key":"e_1_2_10_30_2","first-page":"1483","article-title":"Pharmacological actions of the antihypertensive agent N\u2010amidino\u20102\u2010(2,6\u2010dichlorophenyl)acetamide hydrochloride (BS 100\u2013141)","volume":"25","author":"Scholtysik G","year":"1975","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_10_31_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-3565(25)12477-4","article-title":"Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla","volume":"253","author":"Ernsberger P","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198812040-00174"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198812040-00155"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb09370.x"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1987.tb05602.x"},{"key":"e_1_2_10_36_2","first-page":"S29","article-title":"Moxonidine improves insulin sensitivity in insulin\u2010resistant hypertensives","volume":"17","author":"Haenni A","year":"1999","journal-title":"J Hypertens Suppl"},{"key":"e_1_2_10_37_2","first-page":"26","article-title":"Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist","volume":"139","author":"Kaaja R","year":"2004","journal-title":"Int J Clin Pract Suppl"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-820915"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005351"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb14012.x"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15231.x"},{"key":"e_1_2_10_42_2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0022-3565(25)22394-1","article-title":"Is the sympathoinhibitory effect of rilmenidine mediated by alpha\u20102 adrenoceptors or imidazoline receptors","volume":"270","author":"Urban R","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00297-X"},{"key":"e_1_2_10_44_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0022-3565(25)21405-7","article-title":"Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines","volume":"230","author":"Bousquet P","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"e_1_2_10_45_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199512020-00001","article-title":"Imidazoline receptors: From basic concepts to recent developments","volume":"26","author":"Bousquet P","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_10_46_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.52.4.549"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1993.tb13915.x"},{"key":"e_1_2_10_48_2","first-page":"1442","article-title":"Characteristics of the binding of the antihypertensive agent moxonidine to alpha 2\u2010adrenoceptors in rat brain membranes","volume":"38","author":"Ferry D","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_10_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90597-9"},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90430-J"},{"key":"e_1_2_10_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90125-7"},{"key":"e_1_2_10_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb09388.x"},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb09335.x"},{"key":"e_1_2_10_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1838(98)00094-0"},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)01203-1"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(98)00048-X"},{"key":"e_1_2_10_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb32443.x"},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1059412"},{"key":"e_1_2_10_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb32401.x"},{"key":"e_1_2_10_60_2","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0022-3565(25)39600-X","article-title":"Nonadrenergic imidazoline binding sites on human platelets","volume":"267","author":"Piletz JE","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1984.tb08462.x"},{"key":"e_1_2_10_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(84)81350-2"},{"key":"e_1_2_10_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1838(98)00091-5"},{"key":"e_1_2_10_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)01460-7"},{"key":"e_1_2_10_65_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7906055"},{"key":"e_1_2_10_66_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0022-3565(25)24440-8","article-title":"Comparison of the properties of agmatine and endogenous clonidine\u2010displacing substance at imidazoline and alpha\u20102 adrenergic receptors","volume":"272","author":"Piletz JE","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb14988.x"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00169058"},{"key":"e_1_2_10_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703142"},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)82576-1"},{"key":"e_1_2_10_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.08.022"},{"key":"e_1_2_10_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.03662.x"},{"key":"e_1_2_10_73_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404846101"},{"key":"e_1_2_10_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(96)81564-1"},{"key":"e_1_2_10_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(98)01244-9"},{"key":"e_1_2_10_76_2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0022-3565(24)35399-6","article-title":"Imidazoline\u2010binding domains on monoamine oxidase B and subpopulations of enzyme","volume":"292","author":"Raddatz R","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(02)00074-6"},{"key":"e_1_2_10_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01118-7"},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005070"},{"key":"e_1_2_10_80_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.21.11716"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb09364.x"},{"key":"e_1_2_10_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb13191.x"},{"key":"e_1_2_10_83_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-16079"},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.08.018"},{"key":"e_1_2_10_85_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1304.019"},{"key":"e_1_2_10_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb32388.x"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(01)00076-6"},{"key":"e_1_2_10_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-2473-7_8"},{"key":"e_1_2_10_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(90)90312-F"},{"key":"e_1_2_10_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90602-2"},{"issue":"3","key":"e_1_2_10_91_2","doi-asserted-by":"crossref","first-page":"C568","DOI":"10.1152\/ajpcell.1993.264.3.C568","article-title":"Alpha 2\u2010adrenergic, but not imidazole, agonists activate NaCl cotransport in rabbit tracheal epithelial cells","volume":"264","author":"Liedtke CM","year":"1993","journal-title":"Am J Physiol"},{"key":"e_1_2_10_92_2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0026-895X(24)23223-5","article-title":"Coupling of I(1) imidazoline receptors to the cAMP pathway: Studies with a highly selective ligand, benazoline","volume":"57","author":"Greney H","year":"2000","journal-title":"Mol Pharmacol"},{"key":"e_1_2_10_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb32429.x"},{"key":"e_1_2_10_94_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0026-895X(25)08781-4","article-title":"Coupling of I1\u2010imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells","volume":"49","author":"Separovic D","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_10_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1838(98)00099-X"},{"key":"e_1_2_10_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)91981-5"},{"key":"e_1_2_10_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(96)01372-8"},{"key":"e_1_2_10_98_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00632.x"},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1089\/10445490050043290"},{"key":"e_1_2_10_100_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.151.6.1141"},{"key":"e_1_2_10_101_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600291"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1304.054"},{"key":"e_1_2_10_103_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111838200"},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200112000-00001"},{"key":"e_1_2_10_105_2","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00832.2009"},{"key":"e_1_2_10_106_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS20050037"},{"key":"e_1_2_10_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1838(98)00107-6"},{"key":"e_1_2_10_108_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000014212.04920.62"},{"key":"e_1_2_10_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.09.015"},{"key":"e_1_2_10_110_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)37935-2","article-title":"Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB)","volume":"288","author":"Ernsberger P","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_111_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.111153"},{"key":"e_1_2_10_112_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.050468"},{"key":"e_1_2_10_113_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-005-0024-3"},{"key":"e_1_2_10_114_2","first-page":"S129","article-title":"Cross\u2010Talk between I1\u2010imidazoline and insulin receptor signaling: A mechanism for moxonidine's antidiabetic actions","volume":"18","author":"Edwards L","year":"2000","journal-title":"J. Hypertension"},{"key":"e_1_2_10_115_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816010-00008"},{"key":"e_1_2_10_116_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904X20277"},{"key":"e_1_2_10_117_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.5.1093"},{"key":"e_1_2_10_118_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.00158.x"},{"key":"e_1_2_10_119_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00606.x"},{"key":"e_1_2_10_120_2","first-page":"8","article-title":"The influence of antihypertensive agents on plasmatic and vascular\u2010thrombocytic homeostasis in metabolic syndrome","volume":"71","author":"Vengerovskii AI","year":"2008","journal-title":"Eksp Klin Farmakol"},{"key":"e_1_2_10_121_2","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200606050-00007"},{"key":"e_1_2_10_122_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328311cf37"},{"key":"e_1_2_10_123_2","doi-asserted-by":"publisher","DOI":"10.1177\/147323000803600111"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5922.2011.00268.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5922.2011.00268.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T22:56:11Z","timestamp":1741128971000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5922.2011.00268.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,5]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1755-5922.2011.00268.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5922.2011.00268.x","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,5]]}}}